{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:42:07Z","timestamp":1773232927783,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["222S648"],"award-info":[{"award-number":["222S648"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bursa Uludag University, coordinatorship of scientific research","award":["TGA-2022-1086"],"award-info":[{"award-number":["TGA-2022-1086"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-86874-3","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:23:42Z","timestamp":1737213822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-5071","authenticated-orcid":false,"given":"Ceyda","family":"Colakoglu Bergel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3316-316X","authenticated-orcid":false,"given":"Isil Ezgi","family":"Eryilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-424X","authenticated-orcid":false,"given":"Gulsah","family":"Cecener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-883X","authenticated-orcid":false,"given":"Unal","family":"Egeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"86874_CR1","doi-asserted-by":"publisher","first-page":"176517","DOI":"10.1016\/j.ejphar.2024.176517","volume":"971","author":"F Hosseini","year":"2024","unstructured":"Hosseini, F. et al. Inhibition of melanoma cell migration and invasion by natural coumarin auraptene through regulating EMT markers and reducing MMP-2 and MMP-9 activity. Eur. J. Pharmacol. 971, 176517. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176517 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"86874_CR2","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1080\/15384101.2019.1690881","volume":"18","author":"C Yang","year":"2019","unstructured":"Yang, C. et al. MicroRNA-139-5p modulates the growth and metastasis of malignant melanoma cells via the PI3K\/AKT signaling pathway by binding to IGF1R. Cell. Cycle (Georgetown Tex) 18, 3513\u20133524 (2019).","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"86874_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).","journal-title":"J. Transl. Med."},{"key":"86874_CR4","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/cancers12102801","volume":"12","author":"I Proietti","year":"2020","unstructured":"Proietti, I. et al. Mechanisms of acquired BRAF inhibitor resistance in melanoma: A systematic review. Cancers 12, 2801 (2020).","journal-title":"Cancers"},{"key":"86874_CR5","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","volume":"20","author":"H Rizos","year":"2014","unstructured":"Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact. Clin. Cancer Res. 20, 1965\u20131977 (2014).","journal-title":"Clin. Cancer Res."},{"key":"86874_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.6004\/jadpro.2022.13.4.7","volume":"13","author":"J Davis","year":"2022","unstructured":"Davis, J. & Wayman, M. Encorafenib and binimetinib combination therapy in metastatic melanoma. J. Adv. Pract. Oncol. 13, 450\u2013455 (2022).","journal-title":"J. Adv. Pract. Oncol."},{"key":"86874_CR7","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer, R. et al. COLUMBUS 5-Year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J. Clin. Oncol. 40, 4178\u20134188 (2022).","journal-title":"J. Clin. Oncol."},{"key":"86874_CR8","doi-asserted-by":"publisher","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf, D. et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur. J. Cancer 204, 114073 (2024).","journal-title":"Eur. J. Cancer"},{"key":"86874_CR9","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.3390\/cancers14194930","volume":"14","author":"A Schulz","year":"2022","unstructured":"Schulz, A. et al. Head-to-head comparison of BRAF\/MEK inhibitor combinations proposes superiority of encorafenib plus trametinib in melanoma. Cancers 14, 4930 (2022).","journal-title":"Cancers"},{"key":"86874_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.canlet.2015.11.015","volume":"370","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 370, 332\u2013344 (2016).","journal-title":"Cancer Lett."},{"key":"86874_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.canlet.2020.11.036","volume":"499","author":"ML Hartman","year":"2021","unstructured":"Hartman, M. L., Gajos-Michniewicz, A., Talaj, J. A., Mielczarek-Lewandowska, A. & Czyz, M. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells. Cancer Lett. 499, 122\u2013136 (2021).","journal-title":"Cancer Lett."},{"key":"86874_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neo.2018.02.009","volume":"20","author":"L Mologni","year":"2018","unstructured":"Mologni, L. et al. Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells. Neoplasia 20, 467\u2013477 (2018).","journal-title":"Neoplasia"},{"key":"86874_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3892\/ijo.2016.3594","volume":"49","author":"S Caporali","year":"2016","unstructured":"Caporali, S. et al. Targeting the PI3K\/AKT\/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int. J. Oncol. 49, 1164\u20131174 (2016).","journal-title":"Int. J. Oncol."},{"key":"86874_CR14","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1038\/s41467-020-19075-3","volume":"11","author":"R Tripathi","year":"2020","unstructured":"Tripathi, R. et al. Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling. Nat. Commun. 11, 5463 (2020).","journal-title":"Nat. Commun."},{"key":"86874_CR15","doi-asserted-by":"publisher","first-page":"40535","DOI":"10.18632\/oncotarget.5755","volume":"6","author":"NM Fofaria","year":"2015","unstructured":"Fofaria, N. M., Frederick, D. T., Sullivan, R. J., Flaherty, K. T. & Srivastava, S. K. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1\/2 inhibitors in melanoma. Oncotarget 6, 40535\u201340556 (2015).","journal-title":"Oncotarget"},{"key":"86874_CR16","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ijc.31199","volume":"142","author":"SJ Gallagher","year":"2018","unstructured":"Gallagher, S. J. et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int. J. Cancer 142, 1926\u20131937 (2018).","journal-title":"Int. J. Cancer"},{"key":"86874_CR17","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.3390\/cancers13236058","volume":"13","author":"V Patel","year":"2021","unstructured":"Patel, V., Sz\u00e1sz, I., Koroknai, V., Kiss, T. & Bal\u00e1zs, M. Molecular alterations associated with acquired drug resistance during combined treatment with encorafenib and binimetinib in melanoma cell lines. Cancers 13, 6058 (2021).","journal-title":"Cancers"},{"key":"86874_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/molecules25030537","volume":"25","author":"M Michalak","year":"2020","unstructured":"Michalak, M., Lach, M. S., Antoszczak, M., Huczy\u0144ski, A. & Suchorska, W. M. Overcoming resistance to platinum-based drugs in ovarian cancer by salinomycin and its derivatives\u2014An in vitro study. Molecules 25, 537 (2020).","journal-title":"Molecules"},{"key":"86874_CR19","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1093\/nar\/gkv711","volume":"43","author":"S Tarazona","year":"2015","unstructured":"Tarazona, S. et al. Data quality aware analysis of differential expression in RNA-seq with NOISeq R\/Bioc package. Nucleic Acids Res. 43, e140. https:\/\/doi.org\/10.1093\/nar\/gkv711 (2015).","journal-title":"Nucleic Acids Res."},{"key":"86874_CR20","doi-asserted-by":"publisher","first-page":"W415","DOI":"10.1093\/nar\/gkae456","volume":"52","author":"JM Elizarraras","year":"2024","unstructured":"Elizarraras, J. M. et al. WebGestalt 2024: Faster gene set analysis and new support for metabolomics and multi-omics. Nucleic Acids Res. 52, W415\u2013W421 (2024).","journal-title":"Nucleic Acids Res."},{"key":"86874_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: Tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"86874_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/nar\/gkp896","volume":"38","author":"M Kanehisa","year":"2010","unstructured":"Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, 355\u2013360 (2010).","journal-title":"Nucleic Acids Res."},{"key":"86874_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/nar\/gkn863","volume":"37","author":"L Matthews","year":"2009","unstructured":"Matthews, L. et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 37, 619\u2013622 (2009).","journal-title":"Nucleic Acids Res."},{"key":"86874_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/nar\/gkad392","volume":"51","author":"E Aparicio-Puerta","year":"2023","unstructured":"Aparicio-Puerta, E. et al. miEAA 2023: Updates, new functional microRNA sets and improved enrichment visualizations. Nucleic Acids Res. 51, 319\u2013325 (2023).","journal-title":"Nucleic Acids Res."},{"key":"86874_CR25","doi-asserted-by":"publisher","first-page":"e0206239","DOI":"10.1371\/journal.pone.0206239","volume":"13","author":"C Sticht","year":"2018","unstructured":"Sticht, C., De La Torre, C., Parveen, A. & Gretz, N. miRWalk: An online resource for prediction of microRNA binding sites. PLoS ONE 13, e0206239. https:\/\/doi.org\/10.1371\/journal.pone.0206239 (2018).","journal-title":"PLoS ONE"},{"key":"86874_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-020-01000-2","volume":"13","author":"H Chang","year":"2020","unstructured":"Chang, H. & Zou, Z. Targeting autophagy to overcome drug resistance: further developments. J. Hematol. Oncol. 13, 159 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"86874_CR27","first-page":"56","volume":"19","author":"M Schmidt","year":"2021","unstructured":"Schmidt, M. et al. Single-cell trajectories of melanoma cell resistance to targeted treatment. Cancer Biol. Med. 19, 56\u201373 (2021).","journal-title":"Cancer Biol. Med."},{"key":"86874_CR28","doi-asserted-by":"publisher","first-page":"110617","DOI":"10.1016\/j.intimp.2023.110617","volume":"122","author":"ZR Ma","year":"2023","unstructured":"Ma, Z. R. et al. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy. Int. Immunopharmacol. 122, 110617 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"86874_CR29","doi-asserted-by":"publisher","first-page":"166801","DOI":"10.1016\/j.bbadis.2023.166801","volume":"1869","author":"CN P\u00e9rez","year":"2023","unstructured":"P\u00e9rez, C. N. et al. Melanoma cells with acquired resistance to vemurafenib have decreased autophagic flux and display enhanced ability to transfer resistance. Biochim. Biophys. Acta Mol. Basis Dis. 1869, 166801. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166801 (2023).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"86874_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12967-015-0581-2","volume":"13","author":"JE Hernandez-Davies","year":"2015","unstructured":"Hernandez-Davies, J. E. et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J. Transl. Med. 13, 210. https:\/\/doi.org\/10.1186\/s12967-015-0581-2 (2015).","journal-title":"J. Transl. Med."},{"key":"86874_CR31","doi-asserted-by":"publisher","first-page":"114215","DOI":"10.1016\/j.yexcr.2024.114215","volume":"442","author":"KK Datta","year":"2024","unstructured":"Datta, K. K., Kore, H. & Gowda, H. Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells. Exp. Cell Res. 442, 114215. https:\/\/doi.org\/10.1016\/j.yexcr.2024.114215 (2024).","journal-title":"Exp. Cell Res."},{"key":"86874_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R. et al. Encorafenib plus Binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19, 603\u2013615 (2018).","journal-title":"Lancet Oncol."},{"key":"86874_CR33","doi-asserted-by":"publisher","first-page":"14774","DOI":"10.3390\/ijms241914774","volume":"24","author":"AM Elshazly","year":"2023","unstructured":"Elshazly, A. M. & Gewirtz, D. A. The cytoprotective role of autophagy in response to BRAF-targeted therapies. Int. J. Mol. Sci. 24, 14774 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"86874_CR34","doi-asserted-by":"crossref","first-page":"101042831772162","DOI":"10.1177\/1010428317721620","volume":"39","author":"AX Toress-Collado","year":"2017","unstructured":"Toress-Collado, A. X., Nazarian, R. & Jazirehi, A. R. Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier. Tumour Biol. 39, 1010428317721620 (2017).","journal-title":"Tumour Biol."},{"key":"86874_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell 18, 683\u2013695 (2010).","journal-title":"Cancer Cell"},{"key":"86874_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-021-04270-w","volume":"88","author":"N Wang","year":"2021","unstructured":"Wang, N., Wen, J., Ren, W., Wu, Y. & Deng, C. Upregulation of TRIB2 by Wnt\/\u03b2-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib. Cancer Chemother. Pharmacol. 88, 155\u2013164 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"86874_CR37","doi-asserted-by":"publisher","first-page":"E536","DOI":"10.1073\/pnas.1418163112","volume":"112","author":"D Perna","year":"2015","unstructured":"Perna, D. et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc. Natl. Acad. Sci. U.S.A. 112, E536\u2013E545. https:\/\/doi.org\/10.1073\/pnas.1418163112 (2015).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"86874_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fonc.2019.00268","volume":"9","author":"SA Luebker","year":"2019","unstructured":"Luebker, S. A. & Koepsell, S. A. Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. Front. Oncol. 9, 268 (2019).","journal-title":"Front. Oncol."},{"key":"86874_CR39","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/sj.onc.1210412","volume":"26","author":"DM Owens","year":"2007","unstructured":"Owens, D. M. & Keyse, S. M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26, 3203\u20133213 (2007).","journal-title":"Oncogene"},{"key":"86874_CR40","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","volume":"73","author":"D Lake","year":"2016","unstructured":"Lake, D., Corr\u00eaa, S. A. L. & M\u00fcller, J. Negative feedback regulation of the ERK1\/2 MAPK pathway. Cell. Mol. Life Sci. 73, 4397\u20134413 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"86874_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12964-022-00989-y","volume":"20","author":"E Corrales","year":"2022","unstructured":"Corrales, E. et al. PI3K\/AKT signaling allows for MAPK\/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. Cell Commun. Signal. 20, 187 (2022).","journal-title":"Cell Commun. Signal."},{"key":"86874_CR42","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/antiox11112196","volume":"11","author":"Y Pan","year":"2022","unstructured":"Pan, Y. et al. Targeting ferroptosis as a promising therapeutic strategy for ischemia-reperfusion injury. Antioxidants 11, 2196 (2022).","journal-title":"Antioxidants"},{"key":"86874_CR43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10534-017-0037-7","volume":"30","author":"HH Kazan","year":"2017","unstructured":"Kazan, H. H., Urfali-Mamatoglu, C. & Gunduz, U. Iron metabolism and drug resistance in cancer. Biometals 30, 629\u2013641 (2017).","journal-title":"Biometals"},{"key":"86874_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.32604\/or.2023.027815","volume":"31","author":"Y Jin","year":"2023","unstructured":"Jin, Y., Qiu, J., Lu, X., Ma, Y. & Li, G. LncRNA CACNA1G-AS1 up-regulates FTH1 to inhibit ferroptosis and promote malignant phenotypes in ovarian cancer cells. Oncol. Res. 31, 169\u2013179 (2023).","journal-title":"Oncol. Res."},{"key":"86874_CR45","doi-asserted-by":"publisher","first-page":"1252567","DOI":"10.3389\/fphar.2023.1252567","volume":"14","author":"N Ta","year":"2023","unstructured":"Ta, N., Jiang, X., Zhang, Y. & Wang, H. Ferroptosis as a promising therapeutic strategy for melanoma. Front. Pharmacol. 14, 1252567 (2023).","journal-title":"Front. Pharmacol."},{"key":"86874_CR46","doi-asserted-by":"publisher","first-page":"744940","DOI":"10.3389\/fonc.2021.744940","volume":"11","author":"Y Ke","year":"2021","unstructured":"Ke, Y. et al. Low expression of SLC7A11 confers drug resistance and worse survival in ovarian cancer via inhibition of cell autophagy as a competing endogenous RNA. Front. Oncol. 11, 744940 (2021).","journal-title":"Front. Oncol."},{"key":"86874_CR47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12964-023-01296-w","volume":"21","author":"K Khorsandi","year":"2023","unstructured":"Khorsandi, K., Esfahani, H., Ghamsari, S. K. & Lakhshehei, P. Targeting ferroptosis in melanoma: Cancer therapeutics. Cell Commun. Signal. 21, 337 (2023).","journal-title":"Cell Commun. Signal."},{"key":"86874_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-030-62026-4_4","volume":"1301","author":"N Santana-Codina","year":"2021","unstructured":"Santana-Codina, N., Gikandi, A. & Mancias, J. D. The role of NCOA4-mediated ferritinophagy in ferroptosis. Adv. Exp. Med. Biol. 1301, 41\u201357 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"86874_CR49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41420-024-02075-3","volume":"10","author":"Y Le","year":"2024","unstructured":"Le, Y. et al. The emerging role of nuclear receptor coactivator 4 in health and disease: a novel bridge between iron metabolism and immunity. Cell Death Discov. 10, 312 (2024).","journal-title":"Cell Death Discov."},{"key":"86874_CR50","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fnins.2019.00238","volume":"13","author":"M Del Quiles","year":"2019","unstructured":"Del Quiles, M. & Mancias, J. D. NCOA4-mediated ferritinophagy: A potential link to neurodegeneration. Front. Neurosci. 13, 238 (2019).","journal-title":"Front. Neurosci."},{"key":"86874_CR51","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","volume":"196","author":"L Mahoney-S\u00e1nchez","year":"2021","unstructured":"Mahoney-S\u00e1nchez, L. et al. Ferroptosis and its potential role in the physiopathology of Parkinson\u2019s disease. Prog. Neurobiol. 196, 101890. https:\/\/doi.org\/10.1016\/j.pneurobio.2020.101890 (2021).","journal-title":"Prog. Neurobiol."},{"key":"86874_CR52","doi-asserted-by":"publisher","first-page":"1372330","DOI":"10.3389\/fcell.2024.1372330","volume":"12","author":"H Su","year":"2024","unstructured":"Su, H., Peng, C. & Liu, Y. Regulation of ferroptosis by PI3K\/Akt signaling pathway: A promising therapeutic axis in cancer. Front. Cell Dev. Biol. 12, 1372330. https:\/\/doi.org\/10.3389\/fcell.2024.1372330 (2024).","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86874-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86874-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86874-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T03:12:46Z","timestamp":1737256366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86874-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86874"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86874-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2422"}}